Please go to the PowerPak homepage
and select a course.
New Horizons in HER2+ Breast Cancer: Pharmacist-focused Strategies and Insights
This educational activity is presented by Creative Educational Concepts, Inc., and is supported by an independent educational grant from AstraZeneca and Daiichi Sankyo.
This CPE activity is based on the slides and lectures presented by faculty during a live, virtual symposium for the Hematology/Oncology Pharmacy Association’s (HOPA) 16th Annual Conference on Friday, March 13, 2020.
Val R. Adams, PharmD, FCCP, BCOP
University of Kentucky
College of Pharmacy and
Markey Cancer Center
Neelima Denduluri, MD
Virginia Cancer Specialists
Overexpression of HER2, known clinically as HER2-positive disease, is observed in ~20% of all breast cancer cases. HER2-positive breast cancer is generally more invasive, more likely to be aggressively metastatic, apt to develop resistance to therapy, and more rapidly progressive. Fortunately, the advent of targeted therapeutic agents has vastly improved outcomes for patients with HER2-positive disease, and drug development initiatives are also ongoing. Participants of this activity will gain an appreciation of novel treatment approaches in HER2-positive breast cancer, including the emergence of antibody-drug conjugates (ADCs) and their role in shifting the management paradigm. Safety and efficacy profiles of currently approved ADCs will be reviewed, as will clinical data for ADCs being studied in late-stage trials. Finally, using a challenging, case-based format, participants will identify key strategies oncology pharmacists can employ in their clinical practice in an effort to combat resistance, impede progression, and ultimately, optimize treatment outcomes for patients with HER2-positive breast cancer.
This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.
At the conclusion of this enduring activity, participants will be able to:
- Describe the molecular heterogeneity of breast cancer and review how novel treatment approaches such as antibody-drug conjugates (ADCs) are overcoming obstacles in the management of HER2+ disease.
- Examine the safety and efficacy profiles of currently-approved ADCs in breast cancer and evaluate emerging clinical data for agents in late-stage trials.
- Explore current guideline recommendations for the management of HER2+ breast cancer and identify key inflection points in the changing treatment paradigm, including resistance mitigation strategies, novel mechanisms, and toxicity prevention.
- Using a case-based format, assess challenging clinical questions related to the integration of ADCs into practice, and discuss adaptive ways the oncology pharmacist can optimize therapy, anticipate adverse events, and improve outcomes for patients.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-012-H01-P).
Creative Educational Concepts, Inc. certifies this activity for 1.0 hours of participation.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Val R. Adams, PharmD, FCCP, BCOP—has disclosed that he is a consultant for Amgen.
Neelima Denduluri, MD—has disclosed that she is a consultant for Daiichi Sankyo and Seattle Genetics. She receives grant/research support from Amgen, Daiichi Sankyo, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Seattle Genetics, and Synthon.
Jason Bergsbaken, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Media: Internet Web Activity (PowerPoint slides and audio)
To receive a statement of credit, you must:
- Read the target audience, learning objectives, and author disclosures.
- Review the full content of the activity and reflect upon its teaching.
- Complete the questions and evaluation at the end of the activity.
- You must have a passing score of 75% on the post-test. You will have two (2) opportunities to complete the post-test.